



PATENT

Attorney Docket No.: A-72186-1/TAL/DCF

Attorney File No.: 471702-00008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

QI *et al.*

Serial No. 10/804,763

Filing Date: March 19, 2004

For: *Gene Therapy Vectors Having
Reduced Immunogenicity*


Examiner: Not Yet Assigned

Art Unit: 1645

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including listed enclosures, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450:

Dated: February 10, 2005

Signed: 
Brent Yonehara

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
AND
STATEMENT OF RELATEDNESS**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and in accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants wish to draw the attention of the U.S. Patent and Trademark Office to the references cited on the accompanying form PTO/SB/8A. In accordance with 1273 Off. Gaz. Pat. Office 163, 10/19/2004, no copies of U.S. patents and U.S. published applications are enclosed. Copies of all other references are enclosed.

Further, in accordance with the provisions of 37 C.F.R. §§ 1.97(c) and 1.97(e)(1), the undersigned certifies that the references listed on the enclosed substitute for form PTO-1449 marked with an asterisk (*) were first cited in an International Search Report dated November 11, 2004, for a counterpart PCT application PCT/US2004/008567. A copy of the International

Search Report for the counterpart PCT application is enclosed herewith. References cited in the search report and not cited herein have been previously disclosed by Applicants in the instant application.

Further, in satisfaction of the duty of disclosure under 37 C.F.R. § 1.56, and as required by M.P.E.P. § 2001.06(b), Applicant notes that the present application is related to the following pending patent applications:

1. U.S.S.N. 10/804,762, filed March 19, 2004.

Nothing herein shall constitute an admission concerning the contents of any of the cited references, nor shall the inclusion of a reference herein be considered an admission that the reference constitutes prior art against the invention claimed in the above-identified application. Submission of the present document shall not be construed as an admission that a search has been made or that better art does not exist.

As far as is known to the undersigned, this Information Disclosure Statement is being filed within three months of the filing date of a national application, within three months of the date of entry of the national state in an international application, or before the mailing date of a first Office Action on the merits as set forth in 37 C.F.R. § 1.97(b), and therefore no fee is required.

Serial No. 10/804,763
Filing Date: March 19, 2004


While no fee is believed to be due, if this belief is in error the Commissioner is authorized to charge any additional fees, including extension fees or other relief which may be required, or credit any overpayment to Deposit Account No. 50-2319 (Our File No. 471702-00008; Our Docket No. A-72186-1).

Respectfully submitted,
DORSEY & WHITNEY LLP

Dated: 2/10/05
Customer Number: 32940
Dorsey & Whitney LLP
Four Embarcadero Center, Suite 3400
San Francisco, CA 94111-4187
Telephone: (415) 781-1989
Facsimile: (415) 398-3249

By: 
Todd A. Lorenz, Reg. No. 39,754

Attachments : Form PTO/SB/8A, Substitute for form 1449
International Search Report
8 cited references
Return Postcard



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	A-72186-1 [471702-00008]
-------	---	----	---	------------------------	--------------------------

Complete if Known

Application Number	10/804,763
Filing Date	March 19, 2004
First Named Inventor	QI, Yan
Art Unit	1645
Examiner Name	To Be Assigned

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	5,078,998	01-07-1992	Bevan et al.	
	A2	6,060,054	05-09-2000	Staerz	
	A3	6,264,950 B1	07-24-2001	Staerz	
	A4	6,525,029 B1	02-25-1993	Falck-Pedersen et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ³ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	B1	WO 90/10385 A1	09-20-1990	Tykocinski, Mark		
	B2	WO 96/32140 A1	10-17-1996	TKB Associates LP		
	B3 *	WO 99/23229 A1	05-14-1999	Cornell Res. Foundation, Inc.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C1	CONNOLLY, J., et al., "The Lyt-2 molecule recognizes residues in the class I α 3 domain in allogeneic cytotoxic T cell responses," <i>J. Exp. Med.</i> 168(1):325-341 (Jul. 1988).	
	C2	KERN, P., et al., "Structural basis of CD8 coreceptor function revealed by crystallographic analysis of a murine CD8 α ectodomain fragment in complex with H-2K ^b ," <i>Immunity</i> 9(4):519-530 (Oct. 1998).	
	C3	POTTER, T., et al., "Substitution at residue 227 of H-2 class I molecules abrogates recognition by CD7-dependent, but not CD8-independent, cytotoxic T lymphocytes," <i>Nature</i> 337(6202):73-75 (Jan. 1989).	
	C4	SALTER, R., et al., "A binding site for the T-cell co-receptor CD8 on the α 3 domain of HLA-A2," <i>Nature</i> 345(6270):41-46 (May 1990).	
	C5	WOODLE, E., et al., "Anti-human class I MHC antibodies induce apoptosis by a pathway that is distinct from the Fas antigen-mediated pathway," <i>J. Immunol.</i> 158(5):2156-2164 (Mar. 1997).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and selection option 2